NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $210.47 -5.13 (-2.38%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDGL alerts:Sign Up Key Stats Today's Range$208.53▼$216.6650-Day Range$206.58▼$259.1752-Week Range$119.76▼$299.98Volume219,747 shsAverage Volume425,589 shsMarket Capitalization$4.57 billionP/E RatioN/ADividend YieldN/APrice Target$343.83Consensus RatingModerate Buy Company OverviewMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Madrigal Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks83rd Percentile Overall ScoreMDGL MarketRank™: Madrigal Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 209th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMadrigal Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($27.47) to ($17.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 10.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.78% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 3.49%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.92 Percentage of Shares Shorted17.78% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 3.49%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.60 News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Madrigal Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 2 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows3 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,551,490.00 in company stock.Percentage Held by Insiders22.80% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Stock News HeadlinesMadrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with RezdiffraOctober 17 at 1:22 AM | msn.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Rating Reiterated by Cantor FitzgeraldOctober 15 at 2:29 AM | americanbankingnews.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.October 17, 2024 | Porter & Company (Ad)Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded at StockNews.comOctober 12, 2024 | americanbankingnews.comPiper Sandler Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)October 9, 2024 | markets.businessinsider.comBuy Rating on Madrigal Pharmaceuticals: Rezdiffra’s Rising Prescription Rates and Blockbuster Potential Drive Positive OutlookOctober 7, 2024 | markets.businessinsider.comIs John Paulson’s Best Investment Ever a Buy or SellOctober 5, 2024 | msn.comIs John Paulson's Best Investment Ever a Buy or SellOctober 4, 2024 | msn.comSee More Headlines MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $231.38 on January 1st, 2024. Since then, MDGL shares have decreased by 9.0% and is now trading at $210.47. View the best growth stocks for 2024 here. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($7.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.55) by $0.45. Madrigal Pharmaceuticals's quarterly revenue was up 146280.0% on a year-over-year basis. Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' top institutional investors include Rheos Capital Works Inc. (0.46%), Handelsbanken Fonder AB (0.15%), Creative Planning (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Fred B Craves, Paul A Friedman, William John Sibold, Brian Joseph Lynch, Richard S Levy, Robert E Waltermire, James M Daly and Remy Sukhija. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY). Company Calendar Last Earnings8/07/2024Today10/17/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees90Year Founded2011Price Target and Rating Average Stock Price Target$343.83 High Stock Price Target$410.00 Low Stock Price Target$150.00 Potential Upside/Downside+63.4%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($25.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax Margin-3,487.13% Return on Equity-95.61% Return on Assets-66.71% Debt Debt-to-Equity Ratio0.14 Current Ratio8.72 Quick Ratio8.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book10.25Miscellaneous Outstanding Shares21,710,000Free Float16,762,000Market Cap$4.57 billion OptionableOptionable Beta-0.44 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:MDGL) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.